February 7, 2020

Presentation for Investors 3Q FY2019 (April 1- December 31, 2019) Financial Results

Presented by MIYAZAKI Junichi, Director, Senior Executive Vice President & CFO Head of Finance & Accounting Department

Translation of presentation materials for the conference call held on February 7, 2020







3Q FY2019 Actual

(¥billion)

	FY20	18 Actı	ual (A)	FY20	FY2019 Actual (B)			Y Chai (B)-(A)	U U		Outlook (C) Iov. 2019	vs. Outlook (B)-(C)
	1H	3Q	1-3Q Total	1H	3Q	1-3Q Total	1H	3Q	1-3Q Total	3Q	1-3Q Total	3Q
Sales	98.0	43.9	141.9	96.5	41.5	138.0	-1.5	-2.4	-3.9	42.5	139.0	-1.0
Operating Profit	19.4	4.4	23.8	18.0	3.4	21.4	-1.4	-1.0	-2.4	2.6	20.6	+0.8
Non-Operating Income/Expenses	1.2	0.4	1.6	0.6	0.5	1.1	-0.6	+0.1	-0.5	0.3	0.9	+0.2
Ordinary Income	20.6	4.8	25.4	18.6	3.9	22.5	-2.0	-0.9	-2.9	2.9	21.5	+1.0
Extraordinary Profit/Loss	0.0	0.0	0.0	0.9	0.0	0.9	+0.9	+0.0	+0.9	0.0	0.9	+0.0
Net Income (1)	15.4	3.4	18.8	14.5	3.0	17.5	-0.9	-0.4	-1.3	2.3	16.8	+0.7
EBITDA (2)	24.4	7.3	31.7	22.7	6.3	29.0	-1.7	-1.0	-2.7	-	-	-
EPS (¥/share)	103.53	23.11	126.64	98.75	20.76	119.51	-4.78	-2.35	-7.13	-	-	-
OP Margin	19.8%	10.1%	16.8%	18.7%	8.2%	15.5%	-1.1%	-1.9%	-1.3%	6.1%	14.8%	+2.1%
FX Rate (¥/\$)	110	113	111	109	109	109				108	-	
Naphtha (¥/kl) (3)	51,200	54,200	52,400	42,800	41,300	42,300				42,100	-]

(1) Net income = Profit Attributable to Owners of Parent

(2) EBITDA = Operating Profit + Depreciation + Amortization of goodwill

(3) Based on Trade Statistics of Japan Ministry of Finance

3Q FY2019 Highlight

- 1. 3Q Actual
- (1) 3Q (October 1- December 31, 2019)
- 1) vs. 3Q FY2018
- OP down ¥1.0billion (3Q FY2019 ¥3.4billion vs. 3Q FY2018 ¥4.4billion)
- Chemicals OP down due to sales decrease in melamine, TEPIC and environmental related products
- Performance Materials OP up due to substantial sales increase in Display Materials and fixed cost down
- Agro OP down due to Fluralaner sales decrease (reflected in Outlook as of Nov. 2019) despite GRACIA sales increase
- Pharma OP down due to LIVALO sales decrease
- 2) vs. 3Q FY2019 Outlook as of Nov. 2019 (see p2·p12·p28)
- ◆OP above target ¥0.8billion (3Q FY2019 ¥3.4billion vs. 3Q FY2019 Outlook ¥2.6billion)
- Chemicals OP significantly below target due to sales below target mainly in melamine, TEPIC and environmental relates products
- Performance Materials OP above target due to substantial sales increase in Display Materials, recovery of Semis Materials and fixed cost below expectations
- Agro OP above target partly due to some shipments shifted from 4Q FY2019
- Pharma OP below target due to Custom Chemical sales below target
- Net income above target ¥0.7billion (3Q FY2019 ¥3.0billion vs. 3Q FY2019 Outlook ¥2.3billion)
- (2) 1-3Q (April 1- December 31, 2019)
- OP down ¥2.4billion (1-3Q FY2019 ¥21.4billion vs. 1-3Q FY2018 ¥23.8billion)
- Chemicals OP down due to melamine sales decrease and inventory adjustment cost up
- Performance Materials OP up due to substantial sales increase in Display Materials (smartphone and non-smartphone applications of photo-alignment IPS) and fixed cost down
- Agro OP down due to Fluralaner sales decrease despite substantial sales increase in GRACIA
- Pharma OP down due to LIVALO sales decrease (export down, domestic up due to normalized end market inventory) and slight sales decrease in Custom Chemicals


3Q FY2019 Highlight

2. Full Year FY2019 Outlook as of Nov. 2019 (see p28)

No revision

(3Q results above outlook as of Nov. 2019, but 4Q possibly below the outlook)

3. 4Q FY2019 Segment Sales Trend vs. 4Q FY2019 Outlook as of Nov. 2019 (see p11)



_		vs. 4Q FY2019 Sales Outlook as of Nov. 2019	Sales Trend
Chem	Fine Chemicals	1	TEPIC (for both general applications and electronic materials) estimated to be below target. General applications: cheap Chinese products export up, price down and volume down. Electronic materials: continued sluggish operation of customers.
	Basic Chemicals	1	Melamine estimated to be below target due to cheap Chinese export up, price and volume down.
	Display	~	SUNEVER estimated to be above target due to continued strong sales of photo-alignment
P.M	Semis	/	ARC® and Multi layer process materials estimated to be above target due to sudden recovery of operation of major customers
	Inorganic	N	Estimated to be below target due to sales down of SNOWTEX for non-polishing materials, Organo sol and Oilfield materials
Agro	Agro		Estimated to be above target due to acquisition and smooth launch of Quinoxyfen (see p22)
Agro	Fluralaner		Estimated to be in line with target
	LIVALO		Estimated to be in line with target
Pharma	Custom Chemicals		Estimated to be in line with target

4

3Q FY2019 Review

<vs. 3Q FY2019 Outlook as of November 2019>
 (Sales) ◆ Down ¥ 1.0 billion
 (OP) ◆ Up ¥ 0.8 billion
 (Ordinary Income) ◆ Up ¥ 1.0 billion
 (Net Income) ◆ Up ¥ 0.7 billion

- (+) **Performance Materials**
- (-) Chemicals, Agrochemicals, Pharmaceuticals, Trading
- (+) Performance Materials
- (±) Trading
- (-) Chemicals, Agrochemicals, Pharmaceuticals

- (+) Performance Materials, Agrochemicals
- (±) Pharmaceuticals, Trading
- (-) Chemicals
- (+) Performance Materials, Agrochemicals, Trading
- (-) Chemicals, Pharmaceutical

1-3Q FY2019 Review

<vs. 1-3Q FY2018> **billion** (-3%) (-) Chemicals, Performance Materials, (Sales) ◆ Down ¥ 3.9 Agrochemicals, Pharmaceuticals, Trading (OP) **•** Down ¥ 2.4 billion (-10%) (+) Performance Materials (-) Chemicals, Agrochemicals, Pharmaceuticals, Trading billion (-11%) (Ordinary Income) < Down ¥ 2.9 (Extraordinary Income/Loss) < ¥ 0.9 billion (Extraordinary Income) ¥1.7 billion (Gain on sales of investment securities ¥1.7 billion, sales amount ¥2.9 billion, sold 13 listed companies shares, sold 100% of our shareholdings of 3 listed companies) (Extraordinary Loss) ¥0.8 billion (NCC's payment of a fee for a licensing arrangement relating to Fluralaner) (Net Income) ◆ Down ¥ 1.3 billion (-7%) (EPS) **Over** ¥ 7.13

< Shareholders Return (Full Year Outlook)> (Dividend) ◆ 1H ¥42/share, 2H ¥46/share (dividend payout ratio : 42.1%) (1H up ¥2, 2H up ¥4 vs. FY2018) (No revision vs. FY2019 Outlook as of November 2019) (Share Repurchase) ◆¥10.0 billion (¥6.0 billion, 1.27 million shares completed in July 2019 ¥4.0 billion, in process, announced in November 2019) (Share Cancellation) ◆ Cancelled 2.0 million shares in May 2019 and August 2019 (Total Payout Ratio) ◆74.6% (72.0% FY2018 Actual, No revision vs. FY2019 Outlook as of November 2019)

Non-Operating Income/Expenses, Extraordinary Income/Loss

(¥billion)

		FY201 Actual	-	FY2019 Actual			
	1H	3Q	1-3Q Total	1H	3Q	1-3Q Total	
Non-Operating Income	1.78	0.54	2.32	1.36	0.55	1.91	
Interest income, dividend income	0.34	0.36	0.70	0.37	0.31	0.68	
Equity in earnings of affiliates	0.41	0.19	0.60	0.40	0.12	0.52	
Foreign exchange gains	0.31	-0.24	0.07	0.00	0.00	0.00	
Others	0.72	0.23	0.95	0.59	0.12	0.71	
Non-Operating Expenses	0.57	0.18	0.75	0.74	0.13	0.87	
Interest expense	0.06	0.02	0.08	0.07	0.03	0.10	
Loss on disposal of non-current assets	0.32	0.15	0.47	0.20	0.10	0.30	
Foreign exchange losses	0.00	0.00	0.00	0.22	-0.08	0.14	
Others	0.19	0.01	0.20	0.25	0.08	0.33	
Extraordinary Income	0.00	0.00	0.00	1.69	0.04	1.73	
Extraordinary Loss	0.00	0.00	0.00	0.83	0.00	0.83	

h Flows	1-3Q FY2018	1-3Q FY2019	(¥bil
	Actual	Actual	ľ
CF from operating activities	32.4	34.9	
Income before income taxes & non-controlling interests	25.4	23.4	
Loss (gain) on sales of securities	-0.3	-1.7	
Depreciation and amortization	7.9	7.4	
Amortization of goodwill	0.0	0.2	
Income taxes paid	-9.2	-8.2	
Working capital, others	8.6	13.8	
CF from investing activities	-9.7	-12.9	
Purchase of PPE	-7.4	-6.6	
Purchase and sales of investment securities	-0.5	2.6	
Others (1)	-1.8	-8.9	
CF from financing activities	-37.2	-40.0	
Payout to shareholders (dividend)	-11.3	-12.4	
Payout to shareholders (share repurchase)	-5.0	-8.3	
Borrowings	-20.8	-16.7	
Others (2)	-0.1	-2.6	
Effect of exchange rate change on cash & cash equivalents	-0.1	-0.2]
Change in cash & cash equivalents	-14.6	-18.2]
Cash & cash equivalents at the end of period	23.1	18.0	1

(1) 1-3Q FY2019 Actual: Payments for acquisition of the Quinoxyfen Fungicide Product Line -6.3, Others -2.6 (2) 1-3Q FY2019 Actual: Setting up the trust for share repurchase -1.7,

Share repurchase related to Introduction of a performance-linked stock compensation plan -0.8, Others -0.18

Balance Sheets

(¥billion)

					-				()	
	2018/12	2019/3 (A)	2019/12 (B)	Change (B) - (A)		2018/12	2019/3 (A)	2019/12 (B)	Change (B) - (A)	
Current assets	126.3	152.5	125.8	-26.7	Liabilities	46.3	64.9	47.7	-17.2	
Cash	23.1	36.2	18.0	-18.2	Accounts payable	20.3	17.8	19.6	+1.8	
Accounts receivable	48.2	69.2	47.8	-21.4	Borrowings	7.9	26.6	9.9	-16.7	
Inventories	48.9	42.0	50.8	+8.8	Others	18.1	20.5	18.2	-2.3	
Others	6.1	5.1	9.2	+4.1	Net assets	175.3	182.1	177.1	-5.0	
Fixed assets	95.3	94.5	99.0	+4.5	Shareholders' equity	162.9	169.5	165.6	-3.9	
Total PPE	53.9	52.7	52.6	-0.1	Valuation difference on av ailable- for-sale securities	10.2	10.6	10.0	-0.6	
Intangible assets	1.6	1.5	7.5	+6.0	Foreign currency translation adjustment	0.1	0.0	-0.4	-0.4	
Investment securities*	34.6	35.2	33.6	-1.6	Non-controlling interests	1.7	1.7	1.6	-0.1	
Others	5.2	5.1	5.3	+0.2	Remeasurements of defined benefit plans	0.4	0.3	0.3	-0.0	
Total assets	221.6	247.0	224.8	-22.2	Total liabilities & Net assets	221.6	247.0	224.8	-22.2	
*Investment securities					Equity Ratio	78.3%	73.0%	78.0%		
Listed shares	25.0	25.6	23.9	-1.7		-9.3%				
Unlisted shares	2.5	2.5	2.5	-0.0						
Subsidiaries/Associates shares	7.1	7.1	7.2	+0.1	1 = Net Income 17.5 - Dividend and others 21.4					
Total	34.6	35.2	33.6	-1.6	(1)D/E Ratio = (Borrowi	ngs - Cash) /	Shareholde	ers' equity	9	
									9	

(Blank)

FY2018-19 Quarterly Sales by Segment (1)

(¥billion)

-													, <u> </u>
	FY201	8 Actu	al (A)	FY20 1	I9 Actu	al (B)	YO	Y Chan (B)-(A)	-	Outlo	2019 ok (C) ov. 2019	vs. Outlook	FY2019 Outlook as of Nov. 2019
	1H	3Q	1-3Q Total	1H	3Q	1-3Q Total	1H	3Q	1-3Q Total	3Q	1-3Q Total	(B)-(C)	4Q
Chem	17.0	9.6	26.6	16.8	8.7	25.5	-0.2	-0.9	-1.1	10.0	26.8	-1.3	10.5
Fine Chemicals	5.1	2.6	7.7	5.2	2.6	7.8	+0.1	-0.0	+0.1	2.9	8.1	-0.3	3.2
Basic Chemicals	11.9	7.0	18.9	11.6	6.1	17.7	-0.3	-0.9	-1.2	7.1	18.7	-1.0	7.3
Performance Materials	32.0	16.6	48.6	31.4	17.0	48.4	-0.6	+0.4	-0.2	16.2	47.6	+0.8	15.9
Agro	28.7	5.9	34.6	27.9	5.5	33.4	-0.8	-0.4	-1.2	5.2	33.1	+0.3	31.2
Pharma	3.7	1.9	5.6	3.4	1.6	5.0	-0.3	-0.3	-0.6	1.6	5.0	-0.0	2.0
Trading	33.4	18.1	51.5	33.3	17.5	50.8	-0.1	-0.6	-0.7	17.5	50.8	-0.0	16.3
Others	10.5	7.2	17.7	9.8	5.1	14.9	-0.7	-2.1	-2.8	5.5	15.3	-0.4	7.1
Adjustment	-27.3	-15.4	-42.7	-26.1	-13.9	-40.0	+1.2	+1.5	+2.7	-13.5	-39.6	-0.4	-13.0
Total	98.0	43.9	141.9	96.5	41.5	138.0	-1.5	-2.4	-3.9	42.5	139.0	-1.0	70.0


(1) Including inter-segment sales/transfers

FY2018-19 Quarterly OP by Segment

(¥billion)


	FY2018 Actual (A)		al (A)	FY2019 Actual (B)		YOY Change (B)-(A)			FY2019 Outlook (C) as of Nov.2019		vs. Outlook	FY2019 Outlook as of Nov.2019	
	1H	3Q	1-3Q Total	1H	3Q	1-3Q Total	1H	3Q	1-3Q Total	3Q	1-3Q Total	(B)-(C)	4Q
Chem	1.2	1.0	2.2	0.3	0.6	0.9	-0.9	-0.4	-1.3	1.4	1.7	-0.8	1.7
Performance Materials	8.1	4.3	12.4	8.2	4.9	13.1	+0.1	+0.6	+0.7	3.5	11.7	+1.4	3.4
Agro	9.8	-1.3	8.5	9.4	-1.9	7.5	-0.4	-0.6	-1.0	-2.2	7.2	+0.3	12.4
Pharma	0.6	0.4	1.0	0.5	0.1	0.6	-0.1	-0.3	-0.4	0.2	0.7	-0.1	0.4
Trading	1.1	0.6	1.7	1.0	0.6	1.6	-0.1	+0.0	-0.1	0.5	1.5	+0.1	0.6
Others	0.2	0.2	0.4	0.1	0.1	0.2	-0.1	-0.1	-0.2	0.0	0.1	+0.1	0.5
Adjustment	-1.6	-0.8	-2.4	-1.5	-1.0	-2.5	+0.1	-0.2	-0.1	-0.8	-2.3	-0.2	-1.0
Total	19.4	4.4	23.8	18.0	3.4	21.4	-1.4	-1.0	-2.4	2.6	20.6	+0.8	18.0

Chemicals – (A) Recent Financial Performance




3. Recent Financial Performance (¥billion)

*announced in November 2019



2. FY2018 OP Distribution (¥billion)





OP (right)

Chemicals – (B) 1-3Q FY2019 Sales & Profit Review <Sales Review>

Fine Chem	YOY C	hange	vs. Plan as of Nov. 2019		
	3Q	1-3Q	(undisclosed)		
TEPIC	-10%	-1%	Below		
Environmental related products	-16%	-3%	Below		
Total Fine Chem	-6%	-0%	Below		

Two products account for 82%

of total consolidated subsegment sales (1-3Q FY2019)

Basic Chem	YOY C	hange	vs. Plan as of Nov. 2019
Basic Chem	3Q	1-3Q	(undisclosed)
Melamine	-30%	-12%	Below
Urea including AdBlue	+3%	+5%	Above
High purity sulfuric acid	+5%	+1%	Below
Total Basic Chem	-12%	-6%	Below
Three products seen			

Three products account for 40%

of total consolidated subsegment sales (1-3Q FY2019)

3Q FY2019 Review

(Fine Chemicals)

<vs. 3Q FY2018>

Sales of TEPIC down

(both general applications and electronic materials down)

- Sales of environmental related products down
- Sales down, OP down

(Basic Chemicals)

- Sales of melamine down (both domestic and export down) (cheap Chinese export up, price down)
- Sales of urea including AdBlue up
- Sales of high purity sulfuric acid up
- Sales down, OP down

(Total Segment)

Sales down ¥0.9 billion, OP down ¥0.4 billion

<Profit Review>

(¥billion)

	FY2018 Actual (A)	FY2019 Actual (B)	YOY Change (B) - (A)	FY2019 Outlook as of Nov. 2019 (C)	FY2019 Actual vs. Outlook (B) - (C)	FY2018 Actual	FY2019 Actual	FY2019 Outlook as of Nov. 2019
	3Q	3Q	3Q	3Q	3Q	1-3Q	1-3Q	4Q
Sales	9.6	8.7	-0.9	10.0	-1.3	26.6	25.5	10.5
Fine	2.6	2.6	-0.0	2.9	-0.3	7.7	7.8	3.2
Basic	7.0	6.1	-0.9	7.1	-1.0	18.9	17.7	7.3
OP	1.0	0.6	-0.4	1.4	-0.8	2.2	0.9	1.7

1H FY2019 Review :

see presentation materials for 2Q FY2019 (announced on November 8, 2019)

3Q FY2019 Review

<vs. 3Q FY2019 Outlook as of Nov. 2019>

(Fine Chemicals)

Sales of TEPIC below target

(both general applications and electronic materials below target)

- Sales of environmental related products below target
- ♦ Sales below target, OP below target


(Basic Chemicals)

- Sales of melamine below target (both domestic and export below target) (cheap Chinese export up, price down)
- ♦ Sales of high purity sulfuric acid below target
- Sales of urea including AdBlue above target
- ♦ Sales below target, OP below target

(Total Segment)


Sales down ¥1.3 billion, OP down ¥0.8 billion

Performance Materials – (A) Recent Financial Performance



Performance Materials – (B) 1-3Q FY2019 Sales Distribution

*Plan as of November 2019 (undisclosed)



< Display Materials >

SUNEVER : LCD alignment coating

< Semis Materials >

ARC® : Bottom anti-reflective coating for semis

Multi layer process materials (OptiStack®)

< Inorganic >

StiveSNOWTEX :Silica sol for:
polishing materials
(silicon wafer,
compound semiconductors,
semiconductors CMP and etc.)
and non-polishing materials
(NOx reduction catalyst
materials, special steel sheet
and etc.)Organo/Monomer sol :Hard coating materials,
electronic information
materials, resin additiveOilfield materials :For enhancing oil recovery

Performance Materials – (C) 1-3Q FY2019 Sales Review

Display	YOY C	YOY Change				
Materials	3Q	1-3Q	as of Nov. 2019 (undisclosed)			
Total SUNEVER	+9%	+5%	Above			
Other Display Materials (1)	+2%	-20%	Below			
Total Display Materials	+9%	+5%	Above			

Inorganic	YOY C	YOY Change				
gac	3Q	1-3Q	as of Nov. 2019 (undisclosed)			
SNOWTEX	-11%	-5%	Below			
Organo / Monomer Sol	-16%	-13%	Below			
Oilfield Materials	+5%	-48%	Below			
Total Inorganic	-12%	-11%	Below			


	Semiconductors	YOY C	YOY Change							
	Materials	3Q	1-3Q	as of Nov. 2019 (undisclosed)						
	KrF (ARC®)	-3%	-4%	Above						
	ArF (ARC®)	-5%	-3%	Above						
	Total	-4%	-3%	Above						
0	ther Semiconductors Materials (2)	+10%	-2%	Below						
Т	otal Semiconductors Materials	-0%	-3%	Above						

(1) Hole injection layer materials, Repellant bank layer, Alignment materials for LC retarder, etc.

(2) Multi layer process materials (OptiStack®), EUV under layer, CMOS image sensor materials, 3D packaging process materials, etc.

Performance Materials – (D) SUNEVER

<SUNEVER Sales Distribution by Mode>



*Plan as of November 2019 (undisclosed)

**TN : Twisted Nematic, VA : Vertical Alignment, IPS : In-Plane Switching

< SUNEVER Sales Review by Mode>

	YOY C	hange	vs. Plan		
	3Q	1-3Q	as of Nov. 2019 (undisclosed)		
TN			Above	YOY Change	
			Above	+10~+19%	11
VA			Above	+0~+9%	1
IPS			Above	-0~-9%	¥
1F 5			Above	-10~-19%	77
Total	+9%	+5%	Above	-20~-29%	777

Performance Materials – (E) Profit Overview

	FY2018 Actual (A)	FY2019 Actual (B)	YOY Change (B) - (A)	FY2019 Outlook as of Nov. 2019 (C)	FY2019 Actual vs. Outlook (B) - (C)	FY2018 Actual	FY2019 Actual	(¥billion) FY2019 Outlook as of Nov. 2019
	3Q	3Q	3Q	3Q	3Q	1-3Q	1-3Q	4Q
Sales	16.6	17.0	+0.4	16.2	+0.8	48.	6 48.4	15.9
OP	4.3	4.9	+0.6	3.5	+1.4	12.	4 13.1	3.4

other new materials: EUV under layer, CMOS image sensor materials, 3D packaging process materials total

3Q FY2019 Review

<vs. 3Q FY2018>

- SUNEVER sales up (IPS up (photo-alignment up, rubbing down), VA up, TN down)
- Total Semis Materials sales flat (KrF and ArF down, other semis materials up (Multi layer and other new materials up))
- Inorganic Materials sales down (SNOWTEX down, Organo/Monomer sol down, Oilfield materials up)
- Fixed cost down ¥0.5 billion
- Sales up ¥0.4 billion, OP up ¥0.6 billion (OP: DP up, Semis flat, Inorganic down)


3Q FY2019 Review

<vs. 3Q FY2019 Outlook as of Nov. 2019>

- SUNEVER sales above target (IPS above target (photo-alignment above target, rubbing below target), VA and TN above target)
 Total Semis Materials sales above target (KrF and ArF above target, other semis materials below target (multi layer and other new materials below target))
 Inorganic Materials sales below target (SNOWTEX below target, Organo/Monomer sol below target,
 - Oilfield materials below target)
- Fixed cost below expectations (¥0.6 billion)
- Sales up ¥0.8 billion, OP up ¥1.4 billion (OP: DP up, Semis up, Inorganic down)


(Blank)

Agrochemicals – (A) Recent Financial Performance





3. Recent Financial Performance (¥billion)

*announced in November 2019



2. FY2018 OP Distribution (¥billion)





---OP margin


Agrochemicals – (B) 1-3Q FY2019 Sales Review

<Sales Review (Before Discount)>

*in order of FY2018	sales amount	YOY Change	vs. Plan	
Main Products*		1-3Q	as of Nov. 2019 (undisclosed)	
Fluralaner	Animal health products		Below	
ROUNDUP (1)	Herbicide	+10%	Above	⇒See presentation materials for the ROUNDUP business briefing held on January 22, 2020
ALTAIR	Herbicide	//	Above	https://www.nissanchem.co.jp/eng/news_release/release/en2020_01_24.pdf
TARGA	Herbicide		Above	YOY Change
PERMIT	Herbicide		Above	<mark>+10~+19%</mark> //
				<mark>+0∼+9%</mark> /
GRACIA	Insecticide	over +400%	Below	-0~-9% ¥
Total segment	-	-2%	Above	-10~-19% \ \
j				-20~-29%

(1) ROUNDUP AL for general household accounting for 26% of 1-3Q FY2019 ROUNDUP sales

GRACIA Sales (1-3Q FY2019 Actual)



For GRACIA Sales Long-term Growth Forecast, see p38 of presentation materials for 2Q FY2019 (announced on Nov. 8, 2019)

Quintec (Quinoxyfen)

- Acquired the Quinoxyfen product line of fungicides (¥6.3 billion) including Quintec brand from Corteva in November 2019 and started to sell in December 2019
- Protectant fungicide highly effective in controlling powdery mildew in fruits (especially grapes) and vegetables, mainly sold in USA

<Acquisition's estimated PL impact>

(¥billion, round number)

	OP	OP
	0.	+ Amortization
FY2019	0.0	0.3
FY2020	0.0	1.0
Total FY2021-24	1.0	5.5

Sources: our news release announced on December 2, 2019 Amortization: 5 year straight line method subject to audit

Agrochemicals – (C) Fluralaner

Fluralaner

*Invented by NCC and supplied to MSD as

the active pharmaceutical ingredient of BRAVECTO and EXZOLT

*Currently, BRAVECTO series and EXZOLT are available in 100 countries

*Compound patent

Fluralaner's compound patent expires in March 2025,

but many countries have a patent term extension system

Some EU countries including France, Germany – already extended to February 2029

•USA, UK, etc.

- applications under examination

BRAVECTO

*Developed and launched by MSD

*Veterinary medical products providing 12 weeks of continuous protection for dogs and cats

against fleas and ticks with immediate effect, nearly 3 times longer than any monthly products in the market. *Chewable tablet for dogs

April 2014 Europe, June 2014 USA, July 2015 Japan, July 2019 China

*Spot-on solution for dogs and cats July 2016 EU(cats), December 2016 USA(cats) January 2017 USA, Germany, Austria(dogs) June 2018 Japan(cats)

EXZOLT

*A poultry medicine against red mite launched by MSD (administered via drinking water) September 2017 Europe


BRAVECTO Plus

*A broad-spectrum combination spot-on solution for cats to treat internal and external parasite infestations July 2018 Europe December 2019 USA

Fluralaner Quarterly Sales (including royalty)

For sales plan of FY2018-2021 Fluralaner, see p30 of Mid-term Business Plan Vista2021 Stage II presentation materials (announced on 15 May, 2019)





Agrochemicals – (D) Profit Overview

	FY2018 Actual (A)	FY2019 Actual (B)	YOY Change (B) - (A)	FY2019 Outlook as of Nov. 2019 (C)	(B) - (C)	FY2018 Actual	FY2019 Actual	FY2019 Outlook as of Nov. 2019
Sales	3Q 5.9	3Q 5.5	3Q -0.4	3Q 5.2	3Q +0.3	1-3Q 34.6	1-3Q 33.4	4Q 31.2
OP	-1.3	-1.9	-0.6	-2.2	+0.3	8.5	7.5	12.4

3Q FY2019 Review

<vs. 3Q FY2018>


- Sales up : GRACIA(domestic), ALTAIR(domestic and export), ROUNDUP, PERMIT(export)
- Sales down : Fluralaner(shipment shift), TARGA(export)
- Fixed cost up ¥0.3 billion
 - (including Quinoxyfen amortization ¥0.2 billion)
- Inventory adjustment cost up (¥0.3 billion)
- Sales down ¥0.4 billion, OP down ¥0.6 billion

3Q FY2019 Review


<vs. 3Q FY2019 Outlook as of Nov. 2019>

- Sales above target : ROUNDUP, ALTAIR(domestic and export), TARGA(export), PERMIT(export)
- Sales below target : Fluralaner, GRACIA(export)
- Sales above and below target mainly due to shipment shift between 4Q FY2019 and 3Q (excluding TARGA)
- Fixed cost above expectations ¥0.1 billion (including Quinoxyfen amortization ¥0.2 billion)
- Inventory adjustment cost above expectations (¥0.1 billion)
- Sales up ¥0.3 billion, OP up ¥0.3 billion


Pharmaceuticals – (A) Recent Financial Performance




3. Recent Financial Performance (¥billion)



2. FY2018 OP Distribution (¥billion)





Pharmaceuticals – (B) 1-3Q Sales & Profit Review

<Profit Review>

	FY2018 Actual (A)	FY2019 Actual (B)	YOY Change (B) - (A)	FY2019 Outlook as of Nov. 2019 (C)	FY2019 Actual vs. Outlook (B) - (C)	FY2018 Actual	FY2019 Actual	FY2019 Outlook as of Nov. 2019
Sales	3Q 1.9	3Q 1.6	3Q -0.3	3Q 1.6	3Q -0.0	1-3Q 5.6	1-3Q 5.0	4Q 2.0
OP	0.4	0.1	-0.3	0.2	-0.1	1.0	0.6	0.4

<Sales Review>

	YOY C	hange	vs Plan
	3Q	1-3Q	as of Nov. 2019 (undisclosed)
LIVALO	-23%	-16%	Above
Custom Chemicals	-8%	-3%	Below
Total Segment	-17%	-11%	In Line

3Q FY2019 Review

<vs. 3Q FY2018>

LIVALO sales down (domestic sales up, export down)

Custom Chemicals sales down

Sales down ¥0.3 billion, OP down ¥0.3 billion

3Q FY2019 Review

<vs. 3Q FY2019 Outlook as of Nov. 2019>

LIVALO sales above target

(domestic sales above target, export below target)

- Custom Chemicals sales below target
- Sales flat, OP down ¥0.1 billion

(¥billion)

ESG and Awards

April 2019

Established Nomination and Remuneration Advisory Committee as an optional advisory body of the Board of Directors

June 2019

 Introduced a performance-linked stock compensation plan called a Board Benefit Trust for members of the Board of Directors, etc.

One Outside Director added

As a result, the Board of Directors consisting of 9 Directors include 3 Outside Directors

August 2019

NCC was selected as one of the 50 candidates of the Corporate Value Improvement Award hosted by the Tokyo Stock Exchange for the second consecutive year. The Award targets all listed companies in Japan (approximately 3,600 companies).

September 2019

 NCC was selected as an inclusion in the Dow Jones Sustainability Asia Pacific Index for the second consecutive year

December 2019

• Published "Integrated Reports 2019"

https://www.nissanchem.co.jp/eng/ir_info/archive/ar/ar2019.pdf

Full Year FY2019 Outlook as of Nov. 2019 (no revision afterwards)

(¥billion)

			FY2	018 Ac	tual						2019 (of No					
	1Q	2Q	1H	3Q	4Q	2H	Total	1Q Actual	2Q Actual	1H Actual	3Q	4Q	2H	Tota	al	
Sales	50.9	47.1	98.0	43.9	63.0	106.9	204.9	48.7	47.8	96.5	42.5	70.0	112.5	Record	209.0	
Operating Profit	10.7	8.7	19.4	4.4	13.3	17.7	37.1	9.3	8.7	18.0	2.6	18.0	20.6	Record	38.6	
Non-Operating Income/Expenses	1.2	0.0	1.2	0.4	0.4	0.8	2.0	0.7	-0.1	0.6	0.3	0.2	0.5	1.1		
Ordinary Income	11.9	8.7	20.6	4.8	13.7	18.5	39.1	10.0	8.6	18.6	2.9	18.2	21.1	Record	39.7	
Extraordinary Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.9	0.0	0.0	0.0		0.9	
Net Income (1)	8.8	6.6	15.4	3.4	10.6	14.0	29.4	7.8	6.7	14.5	2.3	13.8	16.1	Record	30.6	
EBITDA (2)	13.1	11.3	24.4	7.3	16.3	23.6	48.0	11.6	11.1	22.7	-	-	26.2		48.9	
EPS (¥/share) (3)	59.25	44.28	103.53	23.11	71.03	94.14	197.67	53.13	45.62	98.75	-	-	110.17	:	208.92	
Dividend (¥/share)	-	-	40	-	-	42	82	-	-	42	-	-	46		88	
Dividend payout ratio (%)	-	-	-	-	-	-	41.5	-	-	-	-	-	-		42.1	
Total amount of Dividend (3)	-	-	5.9	-	-	6.2	12.1	-	-	6.2	-	-	6.7		12.9	
OP Margin	21.0%	18.5%	19.8%	10.1%	21.1%	16.6%	18.1%	19.2%	18.2%	18.7%	6.1%	25.7%	18.3%		18.5%	
ROE (3)	-	-	-	-	-	-	16.6%	-	-	-	-	-	-		16.8%	
FX Rate (¥/\$)	109	111	110	-	-	112	111	110	107	109	108	108	108			
Naphtha (¥/kl)	48,700	53,500	51,200	-	-	48,400	49,700	45,400	40,200	42,800	42,100	42,100	42,100			

- (1) Net income = Profit Attributable to Owners of Parent
- (2) EBITDA = Operating Profit + Depreciation
- (3) FY2019 Outlook including effects of FY2019 share repurchase program ¥10.0 billion (¥6.0 billion completed in July, 2019 and ¥4.0 billion announced in November 2019)

FY2016 - FY2019 Quarterly Sales by Segment (1)

(¥billion)

		FY2)16 Ac	ctual			FY20)17 Ac	ctual			FY2	018 Ac	ctual		FY20)19 Ao	ctual	FY2019 Outlook as of Nov. 2019	
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	3Q	4Q
Chem	8.5	8.0	9.1	9.2	34.8	8.8	7.9	9.2	9.0	34.9	8.7	8.3	9.6	9.1	35.7	8.4	8.4	8.7	10.0	10.5
Fine	2.8	2.5	2.7	2.7	10.7	2.8	2.5	2.8	2.5	10.6	2.7	2.4	2.6	2.7	10.4	2.6	2.6	2.6	2.9	3.2
Basic	5.7	5.5	6.4	6.5	24.1	6.0	5.4	6.4	6.5	24.3	6.0	5.9	7.0	6.4	25.3	5.8	5.8	6.1	7.1	7.3
P.M	12.6	12.9	13.8	13.5	52.8	14.1	15.0	15.1	14.6	58.8	15.6	16.4	16.6	14.4	63.0	15.1	16.3	17.0	16.2	15.9
Agro	14.5	9.5	4.2	23.8	52.0	14.6	11.5	6.4	25.6	58.1	16.4	12.3	5.9	28.1	62.7	14.7	13.2	5.5	5.2	31.2
Pharma	2.2	1.5	2.4	1.9	8.0	2.1	1.4	2.3	1.7	7.5	1.8	1.9	1.9	1.4	7.0	1.9	1.5	1.6	1.6	2.0
Trading	14.4	13.2	13.7	13.9	55.2	14.6	14.5	15.9	14.5	59.5	17.8	15.6	18.1	16.4	67.9	17.5	15.8	17.5	17.5	16.3
Others	4.0	4.6	5.8	9.6	24.0	5.4	4.3	4.6	7.2	21.5	4.6	5.9	7.2	6.9	24.6	4.9	4.9	5.1	5.5	7.1
Adjust	-11.1	-10.3	-11.4	-13.7	-46.5	-12.2	-11.0	-11.8	-11.9	-46.9	-14.0	-13.3	-15.4	-13.3	-56.0	-13.8	-12.3	-13.9	-13.5	-13.0
Total	45.1	39.4	37.6	58.2	180.3	47.4	43.6	41.7	60.7	193.4	50.9	47.1	43.9	63.0	204.9	48.7	47.8	41.5	42.5	70.0

(1) Including inter-segment sales/transfers


FY2016 - FY2019 Quarterly OP by Segment

(¥billion)

		FY2	016 A	ctual			FY2)17 A	ctual			FY2	018 A	ctual		FY20)19 Aa	FY2019 Outlook as of Nov. 2019		
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	3Q	4Q
Chem	1.5	-0.2	1.3	1.2	3.8	1.5	-0.2	1.2	0.9	3.4	1.6	-0.4	1.0	0.8	3.0	0.9	-0.6	0.6	1.4	1.7
P.M	3.0	3.2	3.8	2.5	12.5	3.6	4.1	4.0	2.5	14.2	3.9	4.2	4.3	2.6	15.0	3.9	4.3	4.9	3.5	3.4
Agro	4.5	2.4	-2.0	8.3	13.2	4.5	3.6	-0.6	8.9	16.4	5.1	4.7	-1.3	9.9	18.4	4.5	4.9	-1.9	-2.2	12.4
Pharma	0.6	0.0	0.8	0.3	1.7	0.5	0.0	0.6	0.1	1.2	0.3	0.3	0.4	0.0	1.0	0.4	0.1	0.1	0.2	0.4
Trading	0.4	0.4	0.5	0.4	1.7	0.4	0.5	0.5	0.4	1.8	0.6	0.5	0.6	0.3	2.0	0.5	0.5	0.6	0.5	0.6
Others	0.0	0.0	0.2	0.8	1.0	0.1	0.1	0.1	0.3	0.6	0.1	0.1	0.2	0.5	0.9	0.1	0.0	0.1	0.0	0.5
Adjust	-0.5	-0.6	-0.6	-0.8	-2.5	-0.6	-0.8	-0.7	-0.5	-2.6	-0.9	-0.7	-0.8	-0.8	-3.2	-1.0	-0.5	-1.0	-0.8	-1.0
Total	9.5	5.2	4.0	12.7	31.4	10.0	7.3	5.1	12.6	35.0	10.7	8.7	4.4	13.3	37.1	9.3	8.7	3.4	2.6	18.0

Our Characteristics - (A) Recording Stable OP Margin

NCC has recorded more than 10% OP margin in 16 consecutive years (FY2003-2018)




Our Characteristics - (B) High ROE


The most important financial indicator for a long time

Target : Maintain above 14% (Mid-Term Plan FY2016-2018) \Rightarrow Achieved in FY2016, 2017 and 2018

FY2018 Actual : 16.6%




32



Our Characteristics - (D) Shareholders Return Policy - Dividend

Gradually increased from 30.7% in FY2015 to 41.5% in FY2018

New Mid-Term Plan FY2019-2021 Target : 42.5% in FY2019, 45% in FY2020 and 2021



Our Characteristics - (E) Shareholders Return Policy - Share Repurchase

- Started share repurchase in 2006 only to enhance ROE
- Repurchased ¥72.5 billion, 38.8 million shares (20.7% of shares issued) in total from FY2006 to FY2018
- Cancelled all repurchased shares

Shareholders Return FY2006 - 2018

Fiscal year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Total
Shares purchased (thousand shares)	3,500	3,399	7,355	0	2,167	0	6,372	3,263	2,764	3,333	2,621	2,292	1,682	38,748
Purchase costs (¥billion)	4.7	5.0	8.0	0.0	2.8	0.0	5.0	5.0	6.0	9.0	9.0	9.0	9.0	72.5
Shares cancelled (thousand shares)	3,000	3,635	7,000	0	3,000	0	6,000	4,000	3,000	2,000	2,000	3,000	2,000	38,635
Shares issued at FY end (million shares)	185	181	174	174	171	171	165	161	158	156	154	151	149	
Treasury shares at FY end (thousand shares)	1,367	1,233	1,660	1,709	885	886	1,258	522	287	1,621	2,242	1,535	1,218	

Share repurchase program

Fiscal year	2018	Actual	2019 Actual	2019 Plan as of Nov. 2019		
Period of repurchase	May 14, 2018 - June 8, 2018	Feb. 12, 2019 - March 4, 2019	May 16, 2019 - July 23, 2019	Nov. 11, 2019 - April 30, 2020		
Total amount (¥billion)	5.0	4.0	6.0	up to 4.0		
Total number of shares repurchased (thousand shares)	976	706	1,270	up to 1,300		

Cancellation of treasury shares

Fiscal year	2019	Actual
Date of cancellation	May 2019	August 2019
Total number of shares cancelled (thousand shares)	1,000	1,000

Cash Management Policy


Aiming to control cash balance around the level of

- = Minimum required level
 - + 1/3 of annual scheduled long-term borrowings repayment
 - + 1/3 of short-term borrowings outstanding + Contingent risk reserves

(Blank)

Our Characteristics- (F-1) R&D Oriented Chemical Company


- FY2018 R&D expenses/sales: 8.7%
- Maintaining above 8% R&D expenses/sales in recent years
- About 40% of profession staff assigned to R&D centers




Our Characteristics- (F-2) R&D Oriented Chemical Company

R&D by segment

	FY2018 Actual							
Segment	Sales (¥billion)	OP (¥billion)	OP margin	R&D expenses (¥billion)	% of Sales			
Chemicals	35.7	3.0	8.4%	0.6	1.7%			
Performance Materials	63.0	15.0	23.8%	8.2	13.0%			
Agrochemicals	62.7	18.4	29.3%	4.5	7.2%			
Pharmaceuticals	7.0	1.0	14.3%	2.5	35.7%			
Others	-	-	-	2.0	-			
Total (including others and adjustment)	204.9	37.1	18.1%	17.8	8.7%			



Long-term Financial Performance Trend



^{*}announced in November 2019

Long Term Financial Performance Trend

(¥billion)

Sales 155.9 161.4 169.1 174.4 169.2 160.2 149.0 154.2 148.6 153.8 163.7 171.2 176.9 180.3 193.4 204.9 209.4 Operating Profit 15.7 17.3 21.7 20.8 24.8 17.4 19.2 19.8 15.5 19.5 22.2 25.3 28.6 31.4 35.0 37.1 38.1 Ordinary Income 14.6 17.4 21.3 21.2 24.4 16.9 19.2 19.4 15.9 20.5 23.7 26.4 29.5 31.7 36.2 39.1 39.1 Net Income 8.7 11.3 13.7 14.0 15.5 10.1 12.8 13.0 11.0 13.8 38.3 40.3 45.5 48.0 48.3 OP Margin 10.0% 10.7% 12.8% 12.0% 14.8% 16.2% 17.4% 18.1% 18.1% 18.5 ROE 13.4% 15.2% 16.1%																		
Operating Profit 15.7 17.3 21.7 20.8 24.8 17.4 19.2 19.8 15.5 19.5 22.2 25.3 28.6 31.4 35.0 37.1 38.4 Ordinary Income 14.6 17.4 21.3 21.2 24.4 16.9 19.2 19.4 15.9 20.5 23.7 26.4 29.5 31.7 36.2 39.1 39.7 Net Income 8.7 11.3 13.7 14.0 15.5 10.1 12.8 13.0 11.0 13.9 16.7 18.2 22.4 24.0 27.1 29.4 30.0 BITDA 26.1 26.9 31.6 30.5 34.5 27.6 30.1 30.2 25.9 29.0 30.8 33.8 38.3 40.3 45.5 48.0 48.5 OP Margin 10.0% 10.7% 12.8% 10.9% 12.9% 10.4% 12.7% 13.6% 14.6% 15.1% 16.1% 16.6% 16.89 15.9% <th></th> <th>2003</th> <th>2004</th> <th>2005</th> <th>2006</th> <th>2007</th> <th>2008</th> <th>2009</th> <th>2010</th> <th>2011</th> <th>2012</th> <th>2013</th> <th>2014</th> <th>2015</th> <th>2016</th> <th>2017</th> <th>2018</th> <th>2019E*</th>		2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019E*
Ordinary Income 14.6 17.4 21.3 21.2 24.4 16.9 19.2 19.4 15.9 20.5 23.7 26.4 29.5 31.7 36.2 39.1 39.1 Net Income 8.7 11.3 13.7 14.0 15.5 10.1 12.8 13.0 11.0 13.9 16.7 18.2 22.4 24.0 27.1 29.4 30.0 EBITDA 26.1 26.9 31.6 30.5 34.5 27.6 30.1 30.2 25.9 29.0 30.8 33.8 38.3 40.3 45.5 48.0 48.3 OP Margin 10.0% 10.7% 12.8% 12.0% 11.9% 9.5% 11.4% 12.7% 14.6% 15.1% 16.1% 14.8% 18.5% ROE 13.4% 15.2% 16.1% 14.7% 15.6% 10.3% 12.6% 11.9% 9.5% 11.4% 12.7% 14.6% 15.1% 16.1% 16.6% 16.8% EPS(#/sha	Sales	155.9	161.4	169.1	174.4	169.2	160.2	149.0	154.2	148.6	153.8	163.7	171.2	176.9	180.3	193.4	204.9	209.0
Net Income 8.7 11.3 13.7 14.0 15.5 10.1 12.8 13.0 11.0 13.9 16.7 18.2 22.4 24.0 27.1 29.4 30.1 EBITDA 26.1 26.9 31.6 30.5 34.5 27.6 30.1 30.2 25.9 29.0 30.8 33.8 38.3 40.3 45.5 48.0 48.3 OP Margin 10.0% 10.7% 12.8% 12.9% 10.4% 12.7% 13.6% 14.8% 16.2% 17.4% 18.1% 18.1% 18.5% ROE 13.4% 15.2% 16.1% 14.7% 15.6% 10.3% 12.6% 11.9% 9.5% 11.4% 12.7% 14.6% 15.1% 16.1% 16.8% 16.8% EPS(¥/share) 46.21 59.77 72.73 75.43 85.15 57.26 74.00 75.94 64.52 83.74 102.11 113.99 143.37 156.97 180.30 197.67 208.92	Operating Profit	15.7	17.3	21.7	20.8	24.8	17.4	19.2	19.8	15.5	19.5	22.2	25.3	28.6	31.4	35.0	37.1	38.6
EBITDA 26.1 26.9 31.6 30.5 34.5 27.6 30.1 30.2 25.9 29.0 30.8 33.8 38.3 40.3 45.5 48.0 48.1 OP Margin 10.0% 10.7% 12.8% 12.0% 14.6% 10.9% 12.8% 12.9% 10.4% 12.7% 13.6% 14.8% 16.2% 17.4% 18.1% 18.5% ROE 13.4% 15.2% 16.1% 14.7% 15.6% 10.3% 12.6% 11.9% 9.5% 11.4% 12.7% 12.6% 14.8% 16.2% 17.4% 18.1% 18.5% ROE 13.4% 15.2% 16.1% 14.7% 15.6% 10.3% 12.6% 11.9% 9.5% 11.4% 12.7% 12.6% 14.8% 16.2% 15.1% 16.1% 16.6% 16.8% EPS(¥/share) 46.21 59.77 72.73 75.43 85.15 57.26 74.00 75.4 64.52 83.74 102.11 113.99 143.37 156.97 180.09 197.67 208.92 201.91 23.8% 184.4	Ordinary Income	14.6	17.4	21.3	21.2	24.4	16.9	19.2	19.4	15.9	20.5	23.7	26.4	29.5	31.7	36.2	39.1	39.7
OP Margin 10.0% 10.7% 12.8% 12.0% 14.6% 10.9% 12.8% 12.9% 10.4% 12.7% 13.6% 14.8% 16.2% 17.4% 18.1% 18.1% 18.5% ROE 13.4% 15.2% 16.1% 14.7% 15.6% 10.3% 12.6% 11.9% 9.5% 11.4% 12.7% 12.6% 14.6% 16.1% 16.1% 16.6% 16.89 EPS(¥/share) 46.21 59.77 72.73 75.43 85.15 57.26 74.00 75.94 64.52 83.74 102.11 113.99 143.37 156.97 180.30 197.67 208.92 Dividend(¥/share) 11 11 15 20 20 22 24 24 26 30 36 44 52 68 82 88 Dividend Payout Ratio 23.8% 18.4% 20.6% 26.5% 23.5% 38.4% 32.4% 31.6% 37.2% 31.0% 29.4% 31.6% 30.7% 33.1% 37.7% 41.5% 42.19 Share Repurchase - -	Net Income	8.7	11.3	13.7	14.0	15.5	10.1	12.8	13.0	11.0	13.9	16.7	18.2	22.4	24.0	27.1	29.4	30.6
ROE 13.4% 15.2% 16.1% 14.7% 15.6% 10.3% 12.6% 11.9% 9.5% 11.4% 12.7% 12.7% 14.6% 15.1% 16.1% 16.6% 16.8% EPS(¥/share) 46.21 59.77 72.73 75.43 85.15 57.26 74.00 75.94 64.52 83.74 102.11 113.99 143.37 156.97 180.30 197.67 208.92 Dividend(¥/share) 11 11 15 20 20 22 24 24 26 30 36 44 52 68 82 83 Dividend(¥/share) 11 11 15 20 20 22 24 24 26 30 36 44 52 68 82 83 Dividend(¥/share) 11 11 15 20 20.5% 23.5% 38.4% 32.4% 31.6% 37.2% 31.0% 29.4% 31.6% 30.7% 33.1% 37.7% 41.5% 42.19 42.19 43.4% 100.1 199.2 208.0 223.9 228.2	EBITDA	26.1	26.9	31.6	30.5	34.5	27.6	30.1	30.2	25.9	29.0	30.8	33.8	38.3	40.3	45.5	48.0	48.9
EPS(¥/share) 46.21 59.77 72.73 75.43 85.15 57.26 74.00 75.94 64.52 83.74 102.11 113.99 143.37 156.97 180.30 197.67 208.92 Dividend(¥/share) 11 11 15 20 20 22 24 24 26 30 36 44 52 68 82 88 Dividend Payout Ratio 23.8% 18.4% 20.6% 26.5% 23.5% 38.4% 32.4% 31.6% 37.2% 31.0% 29.4% 31.6% 30.7% 33.1% 37.7% 41.5% 42.19 Share Repurchase - - - 4.7 5.0 8.0 - 2.8 - 5.0 6.0 9.0 9.0 9.0 10.0 Total Assets 172.6 169.4 183.2 177.3 172.7 172.3 181.4 183.4 190.1 199.2 208.0 223.9 228.2 231.7 246.0 247.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0	OP Margin	10.0%	10.7%	12.8%	12.0%	14.6%	10.9%	12.8%	12.9%	10.4%	12.7%	13.6%	14.8%	16.2%	17.4%	18.1%	18.1%	18.5%
Dividend(¥/share) 11 11 15 20 20 22 24 24 24 26 30 36 44 52 68 82 83 Dividend Payout Ratio 23.8% 18.4% 20.6% 26.5% 23.5% 38.4% 32.4% 31.6% 37.2% 31.0% 29.4% 31.6% 30.7% 33.1% 37.7% 41.5% 42.1% Share Repurchase - - - 4.7 5.0 8.0 - 2.8 - 5.0 5.0 6.0 9.0 9.0 9.0 9.0 9.0 10.0 Total Assets 172.6 169.4 183.2 177.3 172.7 172.3 181.4 183.4 190.1 199.2 208.0 223.9 228.2 231.7 246.0 247.0 247.0 Net Assets 70.4 80.0 93.6 99.3 101.2 96.8 107.7 112.4 119.6 126.7 137.8 151.3 156.9 163.7 176.4 182.1 21.1 Cash 5.9 4.3 8.	ROE	13.4%	15.2%	16.1%	14.7%	15.6%	10.3%	12.6%	11.9%	9.5%	11.4%	12.7%	12.7%	14.6%	15.1%	16.1%	16.6%	16.8%
Dividend Payout Ratio 23.8% 18.4% 20.6% 26.5% 23.5% 38.4% 32.4% 31.6% 37.2% 31.0% 29.4% 31.6% 30.7% 33.1% 37.7% 41.5% 42.1% Share Repurchase - - - 4.7 5.0 8.0 - 2.8 - 5.0 5.0 6.0 9.0 9.0 9.0 9.0 10.0 Total Assets 172.6 169.4 183.2 177.3 172.7 172.3 181.4 183.4 190.1 199.2 208.0 223.9 228.2 231.7 246.0 247.0 Net Assets 70.4 80.0 93.6 99.3 101.2 96.8 107.7 112.4 119.6 126.7 137.8 151.3 156.9 163.7 176.4 182.1 Cash 5.9 4.3 8.5 11.0 7.6 9.7 14.8 21.1 27.9 31.9 30.8 31.3 35.3 35.7 37.7 36.2 Liabilities with Interest 57.4 44.6 41.5 32.4 34.	EPS(¥/share)	46.21	59.77	72.73	75.43	85.15	57.26	74.00	75.94	64.52	83.74	102.11	113.99	143.37	156.97	180.30	197.67	208.92
Share Repurchase - - 4.7 5.0 8.0 - 2.8 - 5.0 5.0 6.0 9.0	Dividend(¥/share)	11	11	15	20	20	22	24	24	24	26	30	36	44	52	68	82	88
Total Assets 172.6 169.4 183.2 177.3 172.7 172.3 181.4 183.4 190.1 199.2 208.0 223.9 228.2 231.7 246.0 247.0 Net Assets 70.4 80.0 93.6 99.3 101.2 96.8 107.7 112.4 119.6 126.7 137.8 151.3 156.9 163.7 176.4 182.1 Cash 5.9 4.3 8.5 11.0 7.6 9.7 14.8 21.1 27.9 31.9 30.8 31.3 35.3 35.7 37.7 36.2 Liabilities with Interest 57.4 44.6 41.5 32.4 34.4 45.5 42.1 39.9 38.9 38.1 36.1 35.1 33.1 30.8 28.6 26.6 Equity Ratio 40.1% 46.4% 50.2% 55.3% 58.7% 60.7% 62.4% 63.0% 65.7% 66.9% 68.1% 69.9% 71.0% 73.0%	Dividend Payout Ratio	23.8%	18.4%	20.6%	26.5%	23.5%	38.4%	32.4%	31.6%	37.2%	31.0%	29.4%	31.6%	30.7%	33.1%	37.7%	41.5%	42.1%
Net Assets 70.4 80.0 93.6 99.3 101.2 96.8 107.7 112.4 119.6 126.7 137.8 151.3 156.9 163.7 176.4 182.1 Cash 5.9 4.3 8.5 11.0 7.6 9.7 14.8 21.1 27.9 31.9 30.8 31.3 35.3 35.7 37.7 36.2 Liabilities with Interest 57.4 44.6 41.5 32.4 34.4 45.5 42.1 39.9 38.9 38.1 36.1 35.1 33.1 30.8 28.6 26.6 Equity Ratio 40.1% 46.4% 50.2% 55.3% 58.0% 55.5% 58.7% 60.7% 62.4% 63.0% 65.7% 66.9% 68.1% 69.9% 71.0% 73.0%	Share Repurchase	-	-	-	4.7	5.0	8.0	-	2.8	-	5.0	5.0	6.0	9.0	9.0	9.0	9.0	10.0
Cash 5.9 4.3 8.5 11.0 7.6 9.7 14.8 21.1 27.9 31.9 30.8 31.3 35.3 35.7 37.7 36.2 Liabilities with Interest 57.4 44.6 41.5 32.4 34.4 45.5 42.1 39.9 38.9 38.1 36.1 35.1 33.1 30.8 28.6 26.6 Equity Ratio 40.1% 46.4% 50.2% 55.3% 58.0% 55.5% 60.7% 62.4% 63.0% 65.7% 66.9% 68.1% 69.9% 71.0% 73.0%	Total Assets	172.6	169.4	183.2	177.3	172.7	172.3	181.4	183.4	190.1	199.2	208.0	223.9	228.2	231.7	246.0	247.0	-
Liabilities with Interest 57.4 44.6 41.5 32.4 34.4 45.5 42.1 39.9 38.9 38.1 36.1 35.1 33.1 30.8 28.6 26.6 Equity Ratio 40.1% 46.4% 50.2% 55.3% 58.0% 55.5% 58.7% 60.7% 62.4% 63.0% 65.7% 66.9% 68.1% 69.9% 71.0% 73.0%	Net Assets	70.4	80.0	93.6	99.3	101.2	96.8	107.7	112.4	119.6	126.7	137.8	151.3	156.9	163.7	176.4	182.1	-
Equity Ratio 40.1% 46.4% 50.2% 55.3% 58.0% 55.5% 58.7% 60.7% 62.4% 63.0% 65.7% 66.9% 68.1% 69.9% 71.0% 73.0%	Cash	5.9	4.3	8.5	11.0	7.6	9.7	14.8	21.1	27.9	31.9	30.8	31.3	35.3	35.7	37.7	36.2	-
	Liabilities with Interest	57.4	44.6	41.5	32.4	34.4	45.5	42.1	39.9	38.9	38.1	36.1	35.1	33.1	30.8	28.6	26.6	-
	Equity Ratio	40 .1%	46.4%	50.2%	55.3%	58.0%	55.5%	58.7%	60.7%	62.4%	63.0%	65.7%	66.9%	68.1%	69.9%	71. 0 %	73.0%	-
Capex 6.6 6.6 9.2 12.1 10.9 13.9 10.1 9.6 8.3 8.1 8.8 9.8 10.2 14.3 13.7 9.9 10.7	Capex	6.6	6.6	9.2	12.1	10.9	13.9	10.1	9.6	8.3	8.1	8.8	9.8	10.2	14.3	13.7	9.9	10.1
Depreciation 10.4 9.6 9.9 9.7 9.7 10.2 11.0 10.4 10.5 9.5 8.5 9.7 8.9 10.5 10.9 10.5	Depreciation	10.4	9.6	9.9	9.7	9.7	10.2	11.0	10.4	10.5	9.5	8.5	8.5	9.7	8.9	10.5	10.9	10.3
R&D Expenses 8.7 8.6 9.2 9.9 12.5 13.7 13.1 12.6 13.6 13.7 14.2 15.0 15.8 16.1 17.2 17.8 17.4	R&D Expenses	8.7	8.6	9.2	9.9	12.5	13.7	13.1	12.6	13.6	13.7	14.2	15.0	15.8	16.1	17.2	17.8	17.5
R&D Expenses/Sales 5.6% 5.3% 5.4% 5.7% 7.4% 8.6% 8.8% 8.2% 9.2% 8.9% 8.7% 8.9% <td>R&D Expenses/Sales</td> <td>5.6%</td> <td>5.3%</td> <td>5.4%</td> <td>5.7%</td> <td>7.4%</td> <td>8.6%</td> <td>8.8%</td> <td>8.2%</td> <td>9.2%</td> <td>8.9%</td> <td>8.7%</td> <td>8.7%</td> <td>8.9%</td> <td>8.9%</td> <td>8.9%</td> <td>8.7%</td> <td>8.4%</td>	R&D Expenses/Sales	5.6%	5.3%	5.4%	5.7%	7.4%	8.6%	8.8%	8.2 %	9.2%	8.9 %	8.7%	8.7%	8.9 %	8.9 %	8.9 %	8.7%	8.4%

*announced in November 2019

Sales and OP by Segment (1) (2)

<Sales (A)>

(¥billion)

	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019E*
Chem	38.1	36.9	34.5	35.5	34.3	34.3	34.8	34.9	35.7	37.3
P.M	38.0	34.0	37.4	42.8	49.4	51.8	52.8	58.8	63.0	63.5
Agro	34.4	33.8	35.4	39.1	45.7	47.5	52.0	58.1	62.7	64.3
Pharma	9.6	10.0	12.7	11.6	8.8	8.7	8.0	7.5	7.0	7.0
Trading	44.1	44.8	46.6	50.7	54.4	55.6	55.2	59.5	67.9	67.1
Others	27.0	20.0	21.2	21.4	20.9	20.9	24.0	21.5	24.6	22.4
Adjust	-37.0	-30.9	-34.0	-37.4	-42.3	-41.9	-46.5	-46.9	-56.0	-52.6
Total	154.2	148.6	153.8	163.7	171.2	176.9	180.3	193.4	204.9	209.0
P (B)>										
										_
Chem	2.4		1.9	1.9	1.9	3.9	3.8	3.4	3.0	
Chem P.M	7.9	4.8	7.2	8.8	12.0	12.0	12.5	14.2	15.0	15.1
Chem P.M Agro	7.9 4.8	4.8 4.4	7.2 5.0	8.8 6.2	12.0 9.2	12.0 10.8	12.5 13.2	14.2 16.4	15.0 18.4	15.1 19.6
Chem P.M Agro Pharma	7.9 4.8 4.4	4.8 4.4 4.6	7.2 5.0 5.2	8.8 6.2 4.9	12.0 9.2 2.3	12.0 10.8 2.0	12.5 13.2 1.7	14.2 16.4 1.2	15.0 18.4 1.0	3.4 15.1 19.6 1.1
Chem P.M Agro Pharma Trading	7.9 4.8 4.4 1.4	4.8 4.4 4.6 1.3	7.2 5.0 5.2 1.4	8.8 6.2 4.9 1.5	12.0 9.2 2.3 1.7	12.0 10.8 2.0 1.8	12.5 13.2 1.7 1.7	14.2 16.4 1.2 1.8	15.0 18.4 1.0 2.0	15.1 19.6 1.1 2.1
Chem P.M Agro Pharma Trading Others	7.9 4.8 4.4	4.8 4.4 4.6	7.2 5.0 5.2	8.8 6.2 4.9	12.0 9.2 2.3	12.0 10.8 2.0	12.5 13.2 1.7	14.2 16.4 1.2	15.0 18.4 1.0	15.1 19.6 1.1 2.1 0.6
Chem P.M Agro Pharma Trading Others Adjust	7.9 4.8 4.4 1.4 1.0	4.8 4.4 4.6 1.3 0.3 -1.5	7.2 5.0 5.2 1.4 0.7	8.8 6.2 4.9 1.5 0.8 -1.9	12.0 9.2 2.3 1.7 0.6	12.0 10.8 2.0 1.8 0.5	12.5 13.2 1.7 1.7 1.0	14.2 16.4 1.2 1.8 0.6	15.0 18.4 1.0 2.0 0.9	15.1 19.6 1.1
P (B)> Chem P.M Agro Pharma Trading Others Adjust Total P Marg	7.9 4.8 4.4 1.4 1.0 -2.1	4.8 4.4 1.3 0.3 -1.5 15.5	7.2 5.0 5.2 1.4 0.7 -1.9	8.8 6.2 4.9 1.5 0.8 -1.9	12.0 9.2 2.3 1.7 0.6 -2.4	12.0 10.8 2.0 1.8 0.5 -2.4	12.5 13.2 1.7 1.7 1.0 -2.5	14.2 16.4 1.2 1.8 0.6 -2.6	15.0 18.4 1.0 2.0 0.9 -3.2	15.1 19.6 1.1 2.1 0.6 -3.3

Segment Assets (D)>

FY2018
28.7
51.3
61.8
9.1
25.5
11.5
59.1
247.0

<ROA (E)=(B)/(D)>

10.5% 29.2% 29.8% 11.0% 7.8% 7.8% 15.0%

<

Chem	6.3%	4.3%	5.5%	5.4%	5.5%	11.4%	10.9%	9.7%	8.4%	9.1%
P.M	20.8%	14.1%	19.3%	20.6%	24.3%	23.2%	23.7%	24.1%	23.8%	23.8%
Agro	14.0%	13.0%	14.1%	15.9%	20.1%	22.7%	25.4%	28.2%	29.3%	30.5%
Pharm a	45.8%	46.0%	40.9%	42.2%	26.1%	23.0%	21.3%	16.0%	14.3%	15.7%
Trading	3.2%	2.9%	3.0%	3.0%	3.1%	3.2%	3.1%	3.0%	2.9%	3.1%
Others	3.7%	1.5%	3.3%	3.7%	2.9%	2.4%	4.2%	2.8%	3.7%	2.7%
Total	<mark>12.9%</mark>	10.4%	12.7%	13.6%	14.8%	<mark>16.2%</mark>	17.4%	18.1%	<mark>18.1%</mark>	18.5%

(1) FY2010-2011 : Former Segmentation, FY2012- : New Segmentation

(2) Including inter-segment sales/transfers

*announced in November 2019

Main Products by Segment

Segment	Products	Main Applications
Chem	◆ Fine Chemicals	
	TEPIC	epoxy compound for LED sealants, solder resist, painting
	Melamine cyanurate	flame retardant
	Environmental product	HI-LITE (chlorinated isocyanuric acid for sterilizing)
	Basic Chemicals	
	Melamine	adhesive agent for plywood
	AdBlue	solution of urea in demineralised water for diesel trucks to reduce NOx
	Ammonia, Sulfuric acid, Nitric acid	
Performance	High purity chemicals Electronic Materials 	agents used for cleaning semiconductors
Materials	SUNEVER	LCD alignment coating
Waterials	ARC®	bottom anti-reflective coating for semiconductors
		multi layer process material for semiconductors (Si-HM/SOC)
	OptiStack®	*ARC® and OptiStack® are registered trade mark of Brewer Science, Inc.
	NHC	protective coating for touch panel
	OPTIFOCUS	microlens material for image sensor application
	ELSOURCE	hole injection layer materials for OLED
	Inorganic Materials	
	SNOWTEX	water dispersed colloidal silica sol for polishing silicon wafers, special steel sheets, NOx
		reduction catalyst, electronic printing materials
	Organo silica sol	film coating, antistatic interference shielding, electronic printing materials
	Monomer sol	resin additive
	Alumina sol	automotive catalyst, electronic printing materials
	SUNCOLLOID	high refractive sol for lens
	CELNAX	antistatic sol for film
	Oilfield materials	for enhancing oil recovery
Agro	◆ Herbicide	
	TARGA	soybean, rapeseed, sugarbeet
	PERMIT	corn, sugarcane, rice
	SIRIUS, ALTAIR	paddy rice
	ROUNDUP	non-selective herbicide for orchard, noncrop land
	♦ Insecticide	
	STARMITE, SANMITE, MITOKOHNE	fruits, tea, vegetables
	GRACIA	vegetables, tea
	◆ Fungicide	
	LEIMAY/ORACLE	vegetables, potato, fruits
	PULSOR, IKARUGA, GREATAM	potato, grape, turf
	(THIFLUZAMIDE)	
	Quintec (Quinoxyfen)	fruits, vegetables
	Animal health products	
	Fluralaner	active substance of BRAVECTO (veterinary medical product for dogs and cats) and EXZOLT
		(for poultry red mites)
Pharma	LIVALO	anti-cholesterol drug
	Custom Chemicals	custom manufacturing and process researching services for pharmaceutical companies
Trading	Nissei Corporation	
Others	Transportation, Landscaping, Engineer	ring, Fertilizer 42

Forward Looking Statements

The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncertainties. Actual results may largely differ from these statements due to various factors which may be beyond company control.

No information in this material is provided as an offer to buy or sell the shares of the company. We urge users of the material to make investment decision based upon own judgment.

